Blood Transfusion Diagnostics: Transforming Blood Safety with Advanced Screening and Diagnostic Innovations

The global blood transfusion diagnostics market was valued at USD 5.18 billion in 2025 and is projected to reach USD 8.44 billion by 2034, expanding at a CAGR of 5.00% during 2026–2034. Market growth is primarily driven by the increasing need for safe and effective blood screening, along with ongoing technological advancements in diagnostic assays and testing solutions.

Market Overview

The blood transfusion diagnostics market plays a critical role in modern healthcare by supporting safe blood collection, screening, grouping, compatibility testing, and transfusion practices. Hospitals, blood banks, diagnostic laboratories, and transfusion centers increasingly rely on accurate diagnostic technologies to minimize transfusion-related risks and improve patient safety.

Blood transfusion diagnostics encompasses technologies and testing procedures used to identify transfusion-transmissible infections, determine blood groups, detect clinically significant antibodies, and establish compatibility between donors and recipients. The growing focus on blood safety, quality assurance, automation, and standardized transfusion practices is strengthening demand for advanced diagnostic solutions.

The World Health Organization recommends screening donated blood for HIV, hepatitis B, hepatitis C, and syphilis, along with ABO and RhD testing to support transfusion safety. WHO also emphasizes quality systems, compatibility testing, haemovigilance, and effective national blood-service infrastructure.

Key Market Growth Drivers

• Growing focus on blood safety: Increasing awareness of transfusion-transmissible infections and adverse transfusion reactions is encouraging healthcare organizations to strengthen screening and compatibility procedures.

• Rising demand for blood transfusions: Blood products remain essential in trauma care, surgery, cancer treatment, cardiovascular procedures, pregnancy-related complications, severe anemia, and chronic blood disorders.

• Expansion of automated testing: Automated immunohematology and blood-screening platforms can improve laboratory productivity, standardization, and consistency while reducing dependence on manual procedures.

• Advances in molecular diagnostics: Molecular technologies, including nucleic acid testing, are supporting more sophisticated approaches to identifying infectious agents and improving blood-screening capabilities.

• Increasing healthcare infrastructure investment: Governments and healthcare organizations are investing in blood centers, diagnostic laboratories, quality-management systems, and transfusion infrastructure, particularly in developing healthcare markets.

Key Dynamics

• Automation and workflow integration: Blood banks and laboratories are increasingly adopting integrated diagnostic systems that connect sample identification, testing, result interpretation, documentation, and traceability.

• Regulatory emphasis on quality: Compliance with national and international standards remains a major consideration for diagnostic manufacturers and healthcare providers.

• Growing importance of haemovigilance: Monitoring transfusion-related adverse events is becoming an important component of comprehensive patient-safety programs. WHO identifies haemovigilance and surveillance as important elements of stronger blood systems.

• Centralization of testing: Centralized blood-donation testing and processing can support greater standardization and efficient use of laboratory resources, particularly where blood services are being consolidated.

• Digital transformation: Laboratory information systems, connectivity, automation, and data analytics are creating opportunities to improve traceability and operational efficiency across the transfusion chain.

• Unequal access to screening infrastructure: Significant differences remain between countries in testing capacity and quality systems, creating both a challenge and a long-term opportunity for diagnostic technology providers.

Key Market Players 

• Abbott Laboratories

• Bio-Rad Laboratories, Inc.

• Diamond Diagnostics

• Diagnostica Stago

• Electro Medical Technologies

• F. Hoffmann-La Roche Ltd

• Grifols S.A.

• Immucor Inc.

• Ortho Clinical Diagnostics

• Quotient Ltd.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:

https://www.polarismarketresearch.com/industry-analysis/global-blood-transfusion-diagnostics-market

Market Challenges and Opportunities

Market Challenges

• High implementation costs: Advanced analyzers, molecular testing platforms, laboratory automation, and associated infrastructure can require substantial investment.

• Complex regulatory requirements: Diagnostic technologies must meet stringent quality, safety, validation, and regulatory requirements, potentially extending commercialization timelines.

• Shortage of skilled professionals: Sophisticated blood-screening and immunohematology technologies require trained laboratory personnel capable of operating equipment and interpreting results.

• Supply-chain constraints: Irregular availability of diagnostic kits, reagents, consumables, and quality-control materials can affect testing continuity, particularly in resource-constrained regions. WHO specifically identifies irregular supplies of testing kits as one factor affecting the ability of some healthcare systems to adequately screen donated blood.

Market Opportunities

• Emerging-market expansion: Improving blood-transfusion infrastructure in developing countries creates opportunities for affordable, reliable, and scalable diagnostic technologies.

• Point-of-care testing: Faster diagnostic approaches could support selected emergency and transfusion-related workflows where rapid decisions are important.

• AI and data analytics: Artificial intelligence and advanced analytics may help laboratories optimize workflows, identify anomalies, monitor quality indicators, and improve operational decision-making.

• Integrated diagnostic platforms: Vendors that combine blood screening, immunohematology, automation, information management, and traceability can address broader laboratory requirements.

• Public-private collaboration: Partnerships between governments, hospitals, blood banks, technology providers, and research organizations can help strengthen national blood systems and expand access to quality-assured testing.

Market Segmentation

Blood Transfusion Diagnostics, Product Outlook (Revenue - USD Billion, 2021 - 2034)

• Instrument

• Reagents & Kits

• Others

Blood Transfusion Diagnostics, Application Outlook (Revenue - USD Billion, 2021 - 2034)

• Blood Grouping

• Disease Screening

• Serological

• Molecular

Blood Transfusion Diagnostics, End-Use Outlook (Revenue - USD Billion, 2021 - 2034)

• Hospitals

• Blood Banks

• Diagnostic Laboratories

• Others

Future Outlook

The future of the blood transfusion diagnostics market will be shaped by automation, digital connectivity, molecular testing, quality assurance, and the continuing global emphasis on patient safety. Diagnostic providers are expected to focus on technologies capable of delivering accurate results while improving testing speed, workflow efficiency, traceability, and laboratory standardization.

The global healthcare community is also placing greater emphasis on strengthening national blood systems. WHO's updated strategic framework for blood safety highlights priorities including stronger regulation, improved availability and affordability, patient blood management, surveillance, haemovigilance, and collaboration to address emerging risks.

Emerging economies are expected to provide significant opportunities as governments expand blood-center infrastructure, improve quality systems, and increase access to reliable diagnostic testing. India, for example, has been strengthening blood-transfusion services through standardized practices, external quality assessment, updated technical guidance, and digital integration.

As blood transfusion remains an essential component of healthcare, reliable diagnostics will continue to serve as a fundamental safeguard for donors, healthcare professionals, and patients. The industry's long-term direction will depend not only on technological innovation but also on improving equitable access to quality-assured testing and strengthening transfusion systems worldwide.